IRVINE, Calif. Allergan has completed its acquisition of Esprit Pharma Holding and will move rapidly to integrate Esprit into Allergan, according to

Allergan expects to launch Esprit’s bladder control drug Sanctura XR in the first quarter of 2008.

“This is an exciting day for Allergan as we enter into another core specialty market where there is a high unmet need and significant growth potential,” said David E.I. Pyott, Allergan’s chairman of the board and chief executive officer. “The acquisition will help us better serve the needs of the urology community and its patients by offering Sanctura XR, and by further developing a treatment portfolio that addresses the continuum of care for overactive bladder and other urologic disorders.”

Login or Register to post a comment.